TCR-JANUS 衔接蛋白实现双特异性靶向以克服 TCR-T 细胞治疗中的肿瘤异质性
TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.
基于 T 细胞受体（TCR）的免疫疗法受限于肿瘤抗原异质性，后者常导致复发。
97.8分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
人工智能在 TCR-T 治疗中的技术综述
英文原题：Technical review of artificial intelligence in TCR-T therapy.
研究概要
基于T细胞的癌症免疫治疗进展，加上人工智能（AI）的突破，导致AI驱动的分析和预测算法激增。
中文摘要
基于T细胞的癌症免疫治疗进展，加上人工智能（AI）的突破，导致AI驱动的分析和预测算法激增。然而，将这些计算方法转化为临床实践仍存在重大挑战。本文综述了基于AI的T细胞免疫治疗方法的技术趋势，指出了关键局限性和改进潜力，并提出了未来的研究方向，以弥合计算方法与临床实施之间的差距。
展开英文摘要原文
Advances in T cell-based immunotherapy for cancer treatment, coupled with breakthroughs in artificial intelligence (AI), have led to a surge in AI-driven analysis and prediction algorithms. However, significant challenges remain in translating these computational methods into clinical practice. This paper reviews the technical trends in AI-based approaches for T cell-based immunotherapy, identifies key limitations and potentials for improvement, and proposes future research directions to bridge the gap between computational methods and clinical implementation.
论文信息
- 作者
- Lee I、Joo M、Chung JM
- 单位
- School of Electrical and Electronic Engineering, College of Engineering, Yonsei University, Seoul, Republic of Korea.South Korea
- 文献类型
- 综述
- 期刊
- Journal of the National Cancer Center2026 Aug
- 原文标识
- PubMed 42630545 · DOI 10.1016/j.jncc.2025.12.003